definiens: shall mean all Paten t Rights ( all as listed on Exhibit 1.45 ) and all information, materials and other subject matter, an d improvements thereof, relating to ( i ) mutants or the use thereof in screening, ( ii ) the use of novel protein enginee ring techniques and their application in drug disco very, ( iii ) target - directed fragment discovery and maturation to produ ce drug leads, including monophores, extenders and fragments and monophore, extender and fragment libraries for such purposes, or ( iv ) covalent tethering and techn iques related thereto ( e.g., NMR, X - ray, mass spec . AUC, Biacore ) and its use to discover fragments and test binding hypotheses of fragments and leads : ( a ) Controlled by Sunesis or its controlled Affiliates prior to the Original Agreement Effective Date or during the Research Term ; or ( b ) made by Biogen Idec in the course of activities dir ected to the discovery, research, or development of Licensed Com pounds and PDK Compounds ; provided, in the case of ( b ) that such item was made using or derived from Sunes is Core Technology